(Q34646350)

3 August 2017

Statins and chronic heart failure: do we need a large-scale outcome trial? (English)

1 reference

3 August 2017

0 references

chronic heart failure

1 reference

John J McMurray

2

0 references

Henry Krum

series ordinal

1

object named as

Henry Krum

1 reference

PubMed ID

12020481

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Journal of the American College of Cardiology

3 August 2017

1 reference

3 August 2017

39

1 reference

3 August 2017

10

1 reference

3 August 2017

1567-1573

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Coronary artery disease as the cause of incident heart failure in the population

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Sudden death in heart failure: vascular or electrical?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

From coronary artery disease to heart failure: role of the hibernating myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Angiotensin AT1 receptor over-expression in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Reduced dietary fat intake increases parasympathetic activity in healthy premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

An overview of tumor necrosis factor alpha and the failing human heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Inhibition of proinflammatory cytokine production by pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Pravastatin down-regulates inflammatory mediators in human monocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patien

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Does HDL-cholesterol level predict clinical outcome in advanced heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Evidence of oxidative stress in chronic heart failure in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

The effect of coenzyme Q10 in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

The endotoxin-lipoprotein hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Plasma cytokine parameters and mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901827-2

7 January 2021

10.1016/S0735-1097(02)01827-2

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12020481